Lupin Ltd has received a warning letter issued by the USFDA on November 6, 2017 for the formulation manufacturing facilities at Goa and Indore (Pithampur Unit II).
The company had earlier received 3 Form 483 observations in Goa on Apr 7, 2017 and 6 Form 483 observations in Pithampur (Unit II) on May 19, 2017. The company had responded to all the observations.
The company has said that it is disappointed to have received this outcome. While there will be no disruption of existing product supplies from either of these locations, there will likely be a delay of new product approvals from these two facilities.
The company plans to address the concerns raised by the USFDA expeditiously and will work with the USFDA to resolve these issues at the earliest.
Shares of LUPIN LTD. was last trading in BSE at Rs.1034.7 as compared to the previous close of Rs. 1049.25. The total number of shares traded during the day was 46903 in over 1457 trades.
The stock hit an intraday high of Rs. 1055.15 and intraday low of 1030. The net turnover during the day was Rs. 48806020.